Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The landmark SURMOUNT-1 trial demonstrated average weight loss of approximately 20% of body weight over 72 weeks at the highest dose greater than any single-receptor GLP-1 drug
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications primarily used for managing type 2 diabetes and, in some formulations, for weight management in adults with BMI 30 kg/m or 27 kg/m with weight-related comorbidities
DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Eli Lilly, MSD, Novo Nordisk, and Sanofi and has received research operating funds from Boehringer Ingelheim-Eli Lilly Diabetes Alliance, MSD, AstraZeneca, and Novo Nordisk
Achievement of goals in U.S
US$ 27.79
US$ 21.48
US$ 26.20
US$ 21.96
US$ 26.71
US$ 27.65
